CT103A

DRUG2 trials

Sponsors

Nanjing IASO Biotechnology Co., Ltd., Chunrui Li

Conditions

Extramedullary Multiple MyelomaMultiple Myeloma

Phase 1

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Nanjing IASO Biotechnology Co., Ltd.Multiple Myeloma

Start: 2020-04-01End: 2024-06-30Target: 132Updated: 2021-11-23

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Chunrui LiExtramedullary Multiple Myeloma

Start: 2022-01-01End: 2023-12-31Target: 20Updated: 2022-05-24

Related Papers

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Blood2023-11-028 citations

CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).

Journal of Clinical Oncology2023-06-0126 citations

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood2022-11-1519 citations

S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere2022-06-011 citations